

# News Releases

All Years

Search

Go

[Advanced Search](#)

**FEB 28, 2022**

## **Inhibrx Reports Fourth Quarter and Fiscal Year 2021 Financial Results and Recent Corporate Highlights**

**FEB 22, 2022**

## **Inhibrx Announces Amended Loan Agreement with Oxford**

**JAN 4, 2022**

## **Inhibrx Announces Initial Phase 1 Dose Escalation Results for INBRX-106, a Novel Hexavalent OX40 Agonist, in Combination with Keytruda® (Pembrolizumab) Along with Updated Single Agent Data**

**DEC 1, 2021**

## **Inhibrx Receives FDA Orphan-Drug Designation for INBRX-109 in Chondrosarcoma**

**NOV 9, 2021**

## **Inhibrx Reports Third Quarter 2021 Financial Results and Recent Corporate Highlights**

Show 5  per page

[«](#) [1](#) [...](#) [4](#) [5](#) [6](#) [7](#) [8](#) [9](#) [10](#) [...](#) [13](#) [»](#)



<https://inhibrx.investorroom.com/news-releases?o=30>